Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for December 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2021

December 29, 2021

British Medical Groups Express Concern About Inclisiran Rollout

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

News Daily News

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

September 20, 2021

FDA Approves Dabigatran for VTE in Children

News Daily News

FDA Approves Dabigatran for VTE in Children

June 22, 2021

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

News Daily News

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

Michael O'Riordan

June 17, 2021

Xience Cleared in Europe for 1-Month DAPT in High-Bleeding-Risk Patients

News Daily News

Xience Cleared in Europe for 1-Month DAPT in High-Bleeding-Risk Patients

April 06, 2021

TCTMD’s Top 10 Most Popular Stories for March 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2021

April 02, 2021

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

News Daily News

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

February 16, 2021

FDA Approves Evinacumab for Rare Homozygous FH

News Daily News

FDA Approves Evinacumab for Rare Homozygous FH

Michael O'Riordan

February 11, 2021

FDA Approves Vericiguat for High-risk Patients With HF

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.